Prognostic Implications of PD-L1 Expression in Patients With Angiosarcoma

Figures

• 

  Figure 1.. H&E staining and IHC of PD-L1 expression in angiosarcoma. H&E staining (×200) and IHC (×200) of PD-L1 expression in angiosarcoma patients according to (A) PD-L1-negative angiosarcoma and (B) PD-L1-positive epithelioid angiosarcoma. CPS: Combined positive score; H&E: Hematoxylin and eosin; IHC: Immunohistochemistry; PD-L1: Programmed death ligand-1.

• 

  Figure 2.. Swimmer plot for initial metastatic angiosarcoma patients treated with palliative chemotherapy (n = 23). Each patient’s initial treatment is described in the left column. Other regimens include ifosfamide (n = 1); doxorubicin and olaparib (n = 1); mesna, doxorubicin, ifosfamide and dacarbazine (n = 1); etoposide, ifosfamide and cisplatin (n = 1); vincristine, cyclophosphamide and doxorubicin alternatively followed by ifosfamide and etoposide (n = 1). AI: Adriamycin and ifosfamide; CPS: Combined proportion score; PD-L1: Programmed death ligand-1; PFS: Progression-free survival.

• 

  Figure 3.. Survival analysis of initial metastatic angiosarcoma patients (n = 28) with combined positive score ≥1. Kaplan–Meier estimates of (A) PFS (n = 23) and (B) OS (n = 28). CPS: Combined positive score; HR: Hazard ratio; OS: Overall survival; PFS: Progression-free survival.

• 

  Figure 4.. Survival analysis of initial metastatic angiosarcoma patients treated with paclitaxel with a combined positive score of 1 (n = 12) or higher (n = 3). Kaplan–Meier estimates of (A) PFS and (B) OS. CPS: Combined positive score; HR: Hazard ratio; OS: Overall survival; PFS: Progression-free survival.